A proud year: Looking back on 2022
As we approach the end of the year, it’s only natural to reflect on the previous 12 months, whether from a personal or professional perspective and remember what we achieved.
At MAC, it has been another phenomenal year. One that I am immensely proud of.
From the expansion of our services, outstanding staff progression, and being nominated as a finalist in the SCRIP Awards, it really has been an eventful year.
Below, I have highlighted a few of our key achievements I am most proud of:
A huge year of growth
We have had another hugely successful year for the company, seeing an impressive 85%+ growth in revenue. This is testament to the dedication and hard work of all our employees, who have embraced our vision and mission and dedicated themselves to achieving our goals. Thank you!
Expansion of our services and licensing
Our Early Phase Unit established in 2016 and located by the Manchester Foundation Trust has been re-accredited for the 3rd time by the MHRA. We have expanded our GMP capabilities to now include non-sterile products for liquids for internal use, sterile investigational products which include GMOs and vaccines, and authorisation to manufacture narcotics and psychotropic products. This is an exciting development for us and demonstrates our dedication to ensuring we are continuing to evolve to meet the growing needs of our sponsors.
Innovation and development of our clinical trial software
Our in-house software system EnVision® has seen huge developments this year with the addition of new modules ensuring a cutting edge to our clinical trials operations. Our system supports a seamless patient journey.
Continuous CRO expansion: gaining invaluable insight and expertise into psychedelic research
We have had a tremendous year working on many different full-service studies in a wide range of therapy areas. In 2022 we became established as a go-to provider for many psychedelic biotechnology companies and our science groups have both designed and conducted some truly revolutionary work that we hope can make a real impact on the future of treating mental health. We have created an infrastructure of bespoke psychedelic drug testing suites across our centres which we will be continuing to develop into the new year.
Industry recognition as a SCRIP Awards finalist
And finally, although we didn’t take home the award, I am so proud that we were nominated as a finalist for the SCRIP Awards in the Best Contract Research Organization – Specialist Providers category. Our evolution to global CRO over the last years is due to the hard work and dedication of our staff and continued support from our Sponsors. Being nominated as a finalist shows just how far we have come.
Now, as we look forward to 2023, I am excited to continue these efforts to support our Sponsors, patients, and volunteers who we work together with in delivering our mission. We wish you all a happy and successful new year.